The Drug Enforcement Administration's upcoming federal rescheduling hearing is shaping up as a genuine policy contest, not a formality. NORML and Smart Approaches to Marijuana-organizations that sit at opposite poles of the legalization debate-have both filed notices of intent to participate, signaling that the proceeding will surface substantive, adversarial argument rather than quiet administrative process. For licensed cannabis operators, multi-state companies, and compliance professionals, the outcome carries direct implications for how their businesses are taxed, financed, and regulated at the federal level.
What the Hearing Actually Decides-and What It Doesn't
A rescheduling determination under the Controlled Substances Act would move cannabis from Schedule I to a lower classification-most likely Schedule III, as the Department of Health and Human Services previously recommended. That sounds tidy on paper. In practice, though, the change would not automatically produce federal legalization, nor would it immediately resolve the state-federal conflict that makes cannabis banking, interstate commerce, and Section 280E tax treatment so operationally painful for licensed retailers.
Here's the catch: Schedule III status would remove cannabis from the 280E disallowance-the provision of the Internal Revenue Code that currently bars cannabis businesses from deducting ordinary business expenses because they traffic in a Schedule I or II controlled substance. For dispensary operators running on compressed margins, that single change could materially alter profitability. Some multi-state operators carry tax burdens that consume a disproportionate share of gross revenue precisely because 280E prevents them from deducting payroll, rent, cost of goods, and most standard retail operating costs. Rescheduling would not fix the banking problem outright, but it would deliver meaningful tax relief-which, at the store-operations level, is not a small thing.
What the hearing will not resolve is state law. Adult-use and medical cannabis programs in the states that have licensed them operate under their own regulatory frameworks-seed-to-sale tracking, METRC integrations, excise tax structures, testing mandates, packaging and labeling requirements. None of that changes based on federal scheduling status.
The Regulatory and Business Stakes Beyond the Headline
The participation of organized opponents adds procedural weight to the process. An administrative law judge will preside, and the record built during the hearing will matter if any party later challenges the outcome in federal court. That means this isn't a fast-moving story-it's a slow-burn regulatory proceeding whose resolution could stretch well into 2025 or beyond, depending on how contentious the evidentiary record becomes.
Meanwhile, the broader federal policy environment for cannabis-adjacent substances is in active flux. The Department of Veterans Affairs is launching a study on MDMA-assisted therapy for veterans dealing with PTSD and alcohol use disorder-a significant institutional move, given that VA research carries policy weight on Capitol Hill. Veterans Affairs Secretary Doug Collins separately flagged that ibogaine sourcing constraints may slow psychedelic therapy research, underscoring that supply chain challenges don't only affect cannabis operators; they reach into emerging therapeutic research programs as well.
A newly published study on patients with fibromyalgia, rheumatoid arthritis, and osteoarthritis found that cannabis products produced significant improvements in pain, sleep quality, mental health, and general quality of life-with researchers suggesting cannabinoids may serve as an alternative to opioids. The study also noted that participants reported being able to engage more fully in daily activities. This kind of clinical evidence doesn't directly affect dispensary compliance requirements, but it shapes the evidentiary record that rescheduling advocates will bring to the DEA hearing, and it reinforces the patient-demand data that medical cannabis operators cite when pressing for favorable regulatory treatment.
State-Level Moves That Operators Should Track Now
While federal proceedings grind forward, states are making decisions that hit operators' books immediately. Connecticut Governor Ned Lamont signed budget legislation converting the state's cannabis tax from a THC-based tax to a flat 10.75 percent excise tax. That structural change matters for product mix and pricing strategy at the dispensary level-THC-based taxes penalize high-potency SKUs, while a flat excise rate spreads the burden more evenly across the product menu. Whether that benefits individual operators depends on what their inventory looks like and how their wholesale costs are structured.
In Rhode Island, the governor nominated a new chair of the Cannabis Control Commission-a personnel change worth watching, since commission leadership directly shapes licensing pace, compliance enforcement posture, and rulemaking priorities. Oregon regulators filed rule changes affecting the hemp registry application process, and Florida will hold a medical cannabis rules workshop this week. Routine? Mostly. But operators in those states know that rules workshops and commission chair transitions are often where the practical details get settled-what gets flagged in a compliance inspection, how long a license renewal actually takes, what documentation requirements shift.
On the hemp side, leaders of the Marijuana Policy Project said they don't expect Congress to reverse the federal recriminalization of hemp THC products scheduled to take effect in November-with the possible exception of some adjustment to THC limits or treatment of beverages. That's a sobering assessment for the hemp-derived cannabinoid market, which has grown rapidly in retail channels where licensed cannabis cannot yet compete. Operators and brands that built revenue lines around hemp THC products should be stress-testing their product portfolios against the November deadline now, not in October.
Financial Pressure at the Operator Level
Two corporate developments deserve attention from investors and operators watching the multi-state operator segment. Curaleaf Holdings announced a one-for-three reverse stock split, framing it as a step toward U.S. stock exchange uplisting. Reverse splits are a standard capital markets tool, but they also signal that a company is managing share price thresholds-a reflection of the persistent valuation pressure MSOs face in a high-cost, fragmented regulatory environment. TerrAscend, meanwhile, is in receivership in Michigan over outstanding debts. That's a concrete reminder that even established licensed operators carry significant financial risk, particularly in competitive adult-use markets where wholesale pricing has compressed and retail margins remain tight.
The DEA hearing next month is a single proceeding inside a much larger, slower policy shift. But between 280E tax exposure, hemp THC recriminalization, state tax structure changes, and financial stress at the MSO level, the number of variables that licensed cannabis businesses need to track simultaneously is only growing. Whatever the hearing produces, operators who treat federal rescheduling as the only policy lever worth watching are missing most of the picture.
